Lipid Nanoparticles (LNP) Raw Materials Market - Global Forecast to 2029
| 出版社 | MarketsandMarkets |
| 出版年月 | 2024年9月 |
| ページ数 | 317 |
| 図表数 | 451 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global lipid nanoparticles market is expected to reach USD 350.5 million by 2029, from USD 271.8 million in 2024, at a CAGR of 5.2% from 2024 to 2029.
世界の脂質ナノ粒子（LNP）市場は、2024年から2029年まで5.2%のCAGRで成長し、2024年の2億7,180万米ドルから、2029年までに3億5,050万米ドルに達すると予想されています。
The global lipid nanoparticles services market is projected to reach USD 135.5 million in 2024 to USD 238.1 million in 2029, at a CAGR of 11.9% of during the forecast period of 2024 to 2029.
世界の脂質ナノ粒子サービス市場は、2024年から2029年の予測期間中のCAGR 11.9%で、2024年には1億3,550万米ドル、2029年には2億3,810万米ドルに達すると予測されています。
The growth of the lipid nanoparticles market has been significantly driven by the increasing use of lipid nanoparticles by players for the drug development of RNA therapeutics, personalized medicine, oncology & other therapies. Being a novel excipient for injectable therapies, limited regulatory approvals and resulting lack of established regulatory processes for lipid nanoparticle production are likely to deter the growth of the market.
” The Covid-19 commercial application segment was the highest share holding segment by application in 2023.”
The commercial application segment under Covid-19 was the highest share holding segment in 2023 in the global lipid nanoparticles market. Lipid nanoparticles (LNP) usage in mRNA based COVID-19 vaccines due to their ability to enhance the stability and availability of mRNA was one of the drivers for establishing this market. With the decline in COVID-19 vaccinations, it is expected that clinical applications such as development of RNA therapeutics & LNP based drugs for oncology and other indications will drive the growth in this market.
“The US has continued to dominate the lipid nanoparticles market during the forecast period of 2024-2029.”
Two main mRNA-based COVID-19 vaccine producers that have shown success are Pfizer-BioNTech and Moderna, who have generated billions of doses together. With US government initiative such as Operation Warp Speed, US based biopharmaceutical companies have developed signicant capacities for RNA & LNP production as well as capabilities for development of LNP based drugs. Established LNP & RNA ecosystem and drug development activities from pharmaceutical & biotech companies as well as CDMOs are expected to help the US market retain its leadership in lipid nanoparticles development & manufacturing.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers – 45%, CXO & Directors – 30%, and Executives – 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
List of Companies Profiled in the Report:
- Avanti Polar Lipids (Croda International plc) (US)
- Merck KGaA (Germany)
- Evonik Industries AG (Germany)
- IOI Oleo Gmbh (Germany)
- FUJIFILM Pharmaceuticals U.S.A., Inc. (US)
- Nippon Fine Chemical (Japan)
- Recipharm AB (Sweden)
- Emergent (US)
- EUROAPI (France)
- Cayman Chemical (US)
- CordenPharma (Switzerland)
- NOF CORPOTATION (Japan)
- Precision NanoSystems (Canada)
- Gattefossé (France)
- Acuitas Therapeutics (Canada)
- Creative Biolabs (US)
- Curapath (Spain)
- Lipoid Gmbh (Germany)
- Nanocs, Inc. (US)
- MedKoo Biosciences, Inc. (US)
- Polysciences, Inc. (US)
- BIOVECTRA (Canada)
- Ascendia Pharmaceuticals (US)
- Curia Global, Inc. (US)
- Vernal Biosciences (US)
Research Coverage:
This research report categorizes the lipid nanoparticles market by product (ionizable lipids, PEGylated lipids, neutral lipids, phospholipids, kits & reagents, and other formulation materials), by LNP type (solid lipid nanoparticles, nanostructured lipid carriers, and other types), by molecule type (si RNA, m RNA, and other molecules), by application ((commercial (Polyneuropathy, Covid-19), clinical (Covid-19, cancer, other diseases)), by end user (pharmaceutical & biotechnologies companies, CDMO’s, academic & research institutes), by service type (formulation development services, manufacturing services, and other services), by end user of services (pharmaceutical & biotechnologies companies, academic & research institutes), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the lipid nanoparticles market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, services, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the lipid nanoparticles market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall lipid nanoparticles market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Increasing use of lipid nanoparticles in anti-cancer therapies, Increasing use of lipid nanoparticles in RNA-based therapies, Growing government focus on R&D of key players for the development of lipid nanoparticles-based drugs, restraints (Stringent regulations associated lipid nanoparticles, High cost and difficulties for production of lipid nanoparticles), opportunities (Growing demand for advanced drug delivery systems), and Challenges (Formulation related challenges).
- Product Development/Innovation: Detailed insights on newly launched products/services of the lipid nanoparticles market
- Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, new services, untapped geographies, recent developments, and investments in the lipid nanoparticles market
- Competitive Assessment: Avanti Polar Lipids (Croda International plc) (US), Merck KGaA (Germany), Evonik Industries AG (Germany), FUJIFILM Pharmaceuticals U.S.A., Inc. (US), Nippon Fine Chemical (Japan), Recipharm AB (Sweden), Emergent (US), EUROAPI (France), Cayman Chemical (US), CordenPharma (Switzerland), NOF CORPORATION (Japan), IOI Oleo GmbH (Germany), among others in the market.
Table of Contents
1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 31
1.2.1 INCLUSIONS & EXCLUSIONS 31
1.3 MARKET SCOPE 32
1.3.1 MARKETS COVERED 32
1.4 YEARS CONSIDERED 33
1.5 CURRENCY CONSIDERED 33
1.5.1 VALUE UNIT 33
1.6 MARKET STAKEHOLDERS 33
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
2.1.1 SECONDARY DATA 35
2.1.2 PRIMARY DATA 36
2.2 MARKET ESTIMATION METHODOLOGY 37
2.2.1 GLOBAL MARKET ESTIMATION 38
2.2.2 INSIGHTS OF PRIMARY EXPERTS 40
2.3 MARKET GROWTH RATE PROJECTIONS 42
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 44
2.5 RESEARCH ASSUMPTIONS 44
2.6 RESEARCH LIMITATIONS 45
2.7 RISK ANALYSIS 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 51
4.1 LNP RAW MATERIALS & SERVICES MARKET OVERVIEW 51
4.2 ASIA PACIFIC: LNP RAW MATERIALS & SERVICES MARKET, BY PRODUCT 52
4.3 LNP RAW MATERIALS & SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
4.4 LNP RAW MATERIALS MARKET, BY END USER, 2023 54
4.5 LNP SERVICES MARKET, BY END USER, 2023 54
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
5.2 MARKET DYNAMICS 55
5.2.1 DRIVERS 56
5.2.1.1 Increasing use of lipid nanoparticles in anti-cancer research 56
5.2.1.2 High uptake in RNA-based therapeutic research 57
5.2.1.3 Growing government focus on R&D for LNP-based drugs 57
5.2.2 RESTRAINTS 58
5.2.2.1 Stringent regulatory requirements 58
5.2.3 OPPORTUNITIES 59
5.2.3.1 Growing demand for advanced drug delivery systems 59
5.2.4 CHALLENGES 59
5.2.4.1 Challenges associated with LNP formulation 59
5.2.5 INDUSTRY TRENDS 60
5.2.5.1 Growing preference for personalized medicine and targeted drug delivery 60
5.2.5.2 Advancements in mRNA-based vaccine technology 60
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 61
5.4 PRICING ANALYSIS 61
5.4.1 INDICATIVE SELLING PRICE OF LNP PRODUCTS, BY KEY PLAYER 61
5.4.2 INDICATIVE SELLING PRICE, BY PRODUCT 62
5.5 SUPPLY CHAIN ANALYSIS 63
5.6 VALUE CHAIN ANALYSIS 64
5.7 ECOSYSTEM ANALYSIS 68
5.7.1 LNP RAW MATERIALS & SERVICES MARKET: ROLE IN ECOSYSTEM 69
5.8 TECHNOLOGY ANALYSIS 70
5.8.1 KEY TECHNOLOGIES 70
5.8.1.1 Nanotechnology-based drug delivery 70
5.8.1.2 Nucleic acid delivery 70
5.8.2 COMPLEMENTARY TECHNOLOGIES 71
5.8.2.1 Drug encapsulation techniques 71
5.8.2.2 Surface modification and functionalization technologies 71
5.8.3 ADJACENT TECHNOLOGIES 71
5.8.3.1 Biotechnology & genetic engineering technologies 71
5.8.3.2 Nanotechnology-based formulation techniques 72
5.9 PATENT ANALYSIS 72
5.9.1 PATENTS FILED, BY DOCUMENT TYPE, 2014–2023 72
5.9.2 INNOVATION AND PATENT APPLICATIONS 72
5.9.3 TOP APPLICANTS 72
5.10 KEY CONFERENCES & EVENTS, 2024–2025 76
5.11 REGULATORY LANDSCAPE 76
5.11.1 REGULATORY SCENARIO 76
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 78
5.12 PORTER’S FIVE FORCES ANALYSIS 82
5.12.1 DEGREE OF COMPETITION 83
5.12.2 BARGAINING POWER OF SUPPLIERS 83
5.12.3 BARGAINING POWER OF BUYERS 83
5.12.4 THREAT OF SUBSTITUTES 83
5.12.5 THREAT OF NEW ENTRANTS 83
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 84
5.13.1 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LIPID NANOPARTICLES: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 84
5.14 KEY BUYING CRITERIA 84
5.14.1 BUYING CRITERIA FOR LNP RAW MATERIALS 84
5.14.2 BUYING CRITERIA FOR LNP RAW MATERIALS, BY END USER 85
5.14.3 BUYING CRITERIA FOR LNP SERVICES 86
5.14.4 BUYING CRITERIA FOR LNP SERVICES, BY END USER 86
5.15 INVESTMENT & FUNDING SCENARIO 88
5.16 IMPACT OF GENERATIVE AI ON LNP RAW MATERIALS & SERVICES MARKET 89
6 LNP RAW MATERIALS MARKET, BY PRODUCT 90
6.1 INTRODUCTION 91
6.2 IONIZABLE LIPIDS 91
6.2.1 HIGH DEMAND FOR MRNA-BASED VACCINES TO PROPEL MARKET 91
6.3 PEGYLATED LIPIDS 94
6.3.1 GROWING FOCUS ON NUCLEIC ACID MEDICINES TO BOOST DEMAND 94
6.4 NEUTRAL LIPIDS 95
6.4.1 ENHANCED STABILITY AND HIGH UPTAKE IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET 95
6.5 PHOSPHOLIPIDS 97
6.5.1 BIOLOGICAL COMPATIBILITY AND CUSTOMIZATION FEATURES TO SUPPORT MARKET GROWTH 97
6.6 KITS & REAGENTS 100
6.6.1 ADVANCEMENTS IN LNP FORMULATION TECHNIQUES TO DRIVE MARKET 100
6.7 OTHER FORMULATION MATERIALS 101
7 LNP RAW MATERIALS MARKET, BY LNP TYPE 102
7.1 INTRODUCTION 103
7.2 SOLID LIPID NANOPARTICLES (SLNS) 103
7.2.1 ADVANTAGES OVER CONVENTIONAL DRUG CARRIERS TO DRIVE MARKET 103
7.3 NANOSTRUCTURED LIPID CARRIERS (NLCS) 106
7.3.1 HIGH DRUG LOADING CAPACITY TO PROPEL MARKET 106
7.4 OTHER LNP TYPES 108
8 LNP RAW MATERIALS MARKET, BY MOLECULE TYPE 111
8.1 INTRODUCTION 112
8.2 SIRNA 112
8.2.1 GROWING FOCUS ON TARGETED DRUG DELIVERY TO DRIVE MARKET 112
8.3 MRNA 115
8.3.1 GROWING UPTAKE IN VACCINE DEVELOPMENT TO PROPEL MARKET 115
8.4 OTHER MOLECULES 117
9 LNP RAW MATERIALS MARKET, BY APPLICATION 121
9.1 INTRODUCTION 122
9.2 COMMERCIAL APPLICATIONS 122
9.2.1 POLYNEUROPATHY 125
9.2.1.1 Ability to provide targeted & sustained release of therapeutic agents to boost demand 125
9.2.2 COVID-19 127
9.2.2.1 Enhanced stability and distribution of mRNA to drive market 127
9.3 CLINICAL APPLICATIONS 130
9.3.1 COVID-19 132
9.3.1.1 Threat of evolving emerging variants to fuel uptake 132
9.3.2 CANCER 135
9.3.2.1 Increasing focus on oncology therapeutics to drive market 135
9.3.3 OTHER CLINICAL APPLICATIONS 137
10 LNP RAW MATERIALS MARKET, BY END USER 140
10.1 INTRODUCTION 141
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 141
10.2.1 INCREASING DRUG DEVELOPMENT ACTIVITIES TO FUEL MARKET 141
10.3 ACADEMIC & RESEARCH INSTITUTES 144
10.3.1 HIGH FOCUS ON R&D FOR GENE THERAPY AND MEDICATION ADMINISTRATION TO DRIVE MARKET 144
10.4 CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS (CDMOS) 146
10.4.1 GROWING OUTSOURCING OF LNP FORMULATION SERVICES TO PROPEL MARKET 146
11 LNP SERVICES MARKET, BY SERVICE TYPE 149
11.1 INTRODUCTION 150
11.2 FORMULATION DEVELOPMENT SERVICES 150
11.2.1 GROWING FOCUS ON TARGETED & EFFECTIVE DRUG DELIVERY TO PROPEL MARKET 150
11.3 MANUFACTURING SERVICES 151
11.3.1 RISING DEMAND FOR LIPID-BASED CARRIERS FOR GENE THERAPY
AND VACCINE DEVELOPMENT TO DRIVE MARKET 151
11.4 OTHER SERVICES 152
12 LNP SERVICES MARKET, BY END USER 154
12.1 INTRODUCTION 155
12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 155
12.2.1 DRUG DEVELOPMENT & COMMERCIALIZATION TO PROPEL MARKET 155
12.3 ACADEMIC & RESEARCH INSTITUTES 156
12.3.1 ACCESS TO ADVANCED INFRASTRUCTURE AND SPECIALIZED EXPERTISE TO SUPPORT MARKET GROWTH 156
13 LNP RAW MATERIALS & SERVICES MARKET, BY REGION 158
13.1 INTRODUCTION 159
13.2 NORTH AMERICA 160
13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 164
13.2.2 US 165
13.2.2.1 High pharmaceutical R&D expenditure to drive market 165
13.2.3 CANADA 168
13.2.3.1 Growing focus on personalized medicine to drive market 168
13.3 EUROPE 171
13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 174
13.3.2 GERMANY 175
13.3.2.1 Rising development activities for LNP production to drive market 175
13.3.3 UK 177
13.3.3.1 Pioneering research programs for drug delivery systems to boost demand 177
13.3.4 FRANCE 180
13.3.4.1 Government funding for proteomics and genomics research to support market growth 180
13.3.5 ITALY 183
13.3.5.1 Growth in life sciences research to propel market 183
13.3.6 SPAIN 185
13.3.6.1 Growing demand for cancer therapeutics to drive market 185
13.3.7 REST OF EUROPE 188
13.4 ASIA PACIFIC 191
13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 195
13.4.2 CHINA 196
13.4.2.1 Low manufacturing costs and rising outsourcing of services to CDMOs to drive market 196
13.4.3 JAPAN 199
13.4.3.1 Demand for LNP-based mRNA vaccines to fuel market 199
13.4.4 INDIA 201
13.4.4.1 Growth in pharmaceutical industry to drive market 201
13.4.5 SOUTH KOREA 204
13.4.5.1 Rising number of clinical trials to boost demand 204
13.4.6 AUSTRALIA 207
13.4.6.1 Growing requirement for innovative drug delivery systems to propel market 207
13.4.7 REST OF ASIA PACIFIC 210
13.5 LATIN AMERICA 212
13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 216
13.5.2 BRAZIL 216
13.5.2.1 Global manufacturing hub for pharmaceutical drugs to fuel uptake 216
13.5.3 MEXICO 219
13.5.3.1 Large target patient population and demand for novel drug delivery technology to drive market 219
13.5.4 REST OF LATIN AMERICA 222
13.6 MIDDLE EAST 224
13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 228
13.6.2 GCC COUNTRIES 228
13.6.2.1 Economic & healthcare expansion to support market growth 228
13.6.3 REST OF MIDDLE EAST 231
13.7 AFRICA 234
13.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH 234
13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 237
14 COMPETITIVE LANDSCAPE 238
14.1 INTRODUCTION 238
14.2 KEY PLAYER STRATEGY/RIGHT TO WIN 238
14.3 REVENUE ANALYSIS 240
14.4 MARKET SHARE ANALYSIS 241
14.4.1 LNP SERVICES MARKET 242
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 244
14.5.1 STARS 244
14.5.2 EMERGING LEADERS 244
14.5.3 PERVASIVE PLAYERS 244
14.5.4 PARTICIPANTS 245
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 246
14.5.5.1 Company footprint 246
14.5.5.2 Product footprint 247
14.5.5.3 Application footprint 248
14.5.5.4 Service type footprint 249
14.5.5.5 Region footprint 250
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 251
14.6.1 PROGRESSIVE COMPANIES 251
14.6.2 RESPONSIVE COMPANIES 251
14.6.3 DYNAMIC COMPANIES 251
14.6.4 STARTING BLOCKS 251
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 253
14.7 COMPANY VALUATION & FINANCIAL METRICS 254
14.7.1 FINANCIAL METRICS 254
14.7.2 COMPANY VALUATION 255
14.8 BRAND/PRODUCT COMPARISON ANALYSIS 256
14.9 COMPETITIVE SCENARIO 257
14.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 257
14.9.2 DEALS 258
14.9.3 EXPANSIONS 260
15 COMPANY PROFILES 261
15.1 KEY PLAYERS 261
15.1.1 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC) 261
15.1.1.1 Business overview 261
15.1.1.2 Products/Services offered 263
15.1.1.3 Recent developments 264
15.1.1.3.1 Deals 264
15.1.1.4 MnM view 264
15.1.1.4.1 Key strengths 264
15.1.1.4.2 Strategic choices 264
15.1.1.4.3 Weaknesses & competitive threats 264
15.1.2 MERCK KGAA 265
15.1.2.1 Business overview 265
15.1.2.2 Products/Services offered 267
15.1.2.3 Recent developments 268
15.1.2.3.1 Deals 268
15.1.2.3.2 Expansions 268
15.1.2.4 MnM view 269
15.1.2.4.1 Key strengths 269
15.1.2.4.2 Strategic choices 269
15.1.2.4.3 Weaknesses & competitive threats 269
15.1.3 EVONIK INDUSTRIES AG 270
15.1.3.1 Business overview 270
15.1.3.2 Products/Services offered 271
15.1.3.3 Recent developments 272
15.1.3.3.1 Deals 272
15.1.3.4 MnM view 272
15.1.3.4.1 Key strengths 272
15.1.3.4.2 Strategic choices 272
15.1.3.4.3 Weaknesses & competitive threats 272
15.1.4 NIPPON FINE CHEMICAL 273
15.1.4.1 Business overview 273
15.1.4.2 Products/Services offered 274
15.1.4.3 MnM view 275
15.1.4.3.1 Key strengths 275
15.1.4.3.2 Strategic choices 275
15.1.4.3.3 Weaknesses & competitive threats 275
15.1.5 NOF CORPORATION 276
15.1.5.1 Business overview 276
15.1.5.2 Products/Services offered 278
15.1.5.3 Recent developments 279
15.1.5.3.1 Deals 279
15.1.5.4 MnM view 279
15.1.5.4.1 Key strengths 279
15.1.5.4.2 Strategic choices 279
15.1.5.4.3 Weaknesses & competitive threats 279
15.1.6 FUJIFILM PHARMACEUTICALS U.S.A., INC.
(FUJIFILM HOLDINGS CORPORATION) 280
15.1.6.1 Business overview 280
15.1.6.2 Products/Services offered 281
15.1.6.3 Recent developments 282
15.1.6.3.1 Expansions 282
15.1.7 PRECISION NANOSYSTEMS (CYTIVA) 283
15.1.7.1 Business overview 283
15.1.7.2 Products/Services offered 283
15.1.7.3 Recent developments 284
15.1.7.3.1 Product/Service launches 284
15.1.7.3.2 Deals 285
15.1.7.3.3 Expansions 285
15.1.8 RECIPHARM AB 286
15.1.8.1 Business overview 286
15.1.8.2 Products/Services offered 287
15.1.8.3 Recent developments 287
15.1.8.3.1 Deals 287
15.1.9 EMERGENT 288
15.1.9.1 Business overview 288
15.1.9.2 Products/Services offered 289
15.1.9.3 Recent developments 290
15.1.9.3.1 Deals 290
15.1.10 EUROAPI 291
15.1.10.1 Business overview 291
15.1.10.2 Products/Services offered 292
15.1.11 CAYMAN CHEMICAL 293
15.1.11.1 Business overview 293
15.1.11.2 Products/Services offered 293
15.1.12 CORDENPHARMA 294
15.1.12.1 Business overview 294
15.1.12.2 Products/Services offered 294
15.1.12.3 Recent developments 295
15.1.12.3.1 Product/Service launches 295
15.1.12.3.2 Deals 295
15.1.12.3.3 Expansions 295
15.1.13 GATTEFOSSÉ 296
15.1.13.1 Business overview 296
15.1.13.2 Products/Services offered 296
15.1.14 ACUITAS THERAPEUTICS 297
15.1.14.1 Business overview 297
15.1.14.2 Products/Services offered 297
15.1.14.3 Recent developments 298
15.1.14.3.1 Deals 298
15.1.15 IOI OLEO GMBH 299
15.1.15.1 Business overview 299
15.1.15.2 Products/Services offered 300
15.2 OTHER PLAYERS 301
15.2.1 CREATIVE BIOLABS 301
15.2.2 CURAPATH 302
15.2.3 LIPOID GMBH 303
15.2.4 NANOCS INC. 304
15.2.5 MEDKOO BIOSCIENCES, INC. 305
15.2.6 POLYSCIENCES INC. 305
15.2.7 BIOVECTRA 306
15.2.8 ASCENDIA PHARMACEUTICALS 306
15.2.9 CURIA GLOBAL, INC. 307
15.2.10 VERNAL BIOSCIENCES 307
16 APPENDIX 308
16.1 DISCUSSION GUIDE 308
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 313
16.3 CUSTOMIZATION OPTIONS 315
16.4 RELATED REPORTS 315
16.5 AUTHOR DETAILS 316
LIST OF TABLES
TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 43
TABLE 2 RISK ANALYSIS 45
TABLE 3 LNP RAW MATERIALS & SERVICES MARKET: IMPACT ANALYSIS 56
TABLE 4 INDICATIVE PRICING OF LNP PRODUCTS, BY KEY PLAYER 61
TABLE 5 INDICATIVE PRICING OF LNP PRODUCTS, BY TYPE 62
TABLE 6 PATENTS FILED, 2014–2023 72
TABLE 7 INDICATIVE LIST OF PATENTS IN LNP RAW MATERIALS & SERVICES MARKET 74
TABLE 8 LNP RAW MATERIALS & SERVICES MARKET: LIST OF CONFERENCES &
EVENTS (2024−2025) 76
TABLE 9 REGULATORY SCENARIO 78
TABLE 10 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 78
TABLE 11 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 79
TABLE 12 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 80
TABLE 13 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 81
TABLE 14 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 15 LNP RAW MATERIALS & SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 82
TABLE 16 BUYING CRITERIA FOR LNP RAW MATERIALS, BY END USER 85
TABLE 17 LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 91
TABLE 18 IONIZABLE LIPIDS MARKET, BY REGION, 2022–2029 (USD MILLION) 92
TABLE 19 NORTH AMERICA: IONIZABLE LIPIDS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 92
TABLE 20 EUROPE: IONIZABLE LIPIDS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 92
TABLE 21 ASIA PACIFIC: IONIZABLE LIPIDS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 93
TABLE 22 LATIN AMERICA: IONIZABLE LIPIDS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 93
TABLE 23 MIDDLE EAST: IONIZABLE LIPIDS MARKET, BY REGION,
2022–2029 (USD MILLION) 93
TABLE 24 PEGYLATED LIPIDS MARKET, BY REGION, 2022–2029 (USD MILLION) 94
TABLE 25 NEUTRAL LIPIDS MARKET, BY REGION, 2022–2029 (USD MILLION) 95
TABLE 26 NORTH AMERICA: NEUTRAL LIPIDS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 96
TABLE 27 EUROPE: NEUTRAL LIPIDS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 96
TABLE 28 ASIA PACIFIC: NEUTRAL LIPIDS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 96
TABLE 29 LATIN AMERICA: NEUTRAL LIPIDS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 97
TABLE 30 MIDDLE EAST: NEUTRAL LIPIDS MARKET, BY REGION, 2022–2029 (USD MILLION) 97
TABLE 31 PHOSPHOLIPIDS MARKET, BY REGION, 2022–2029 (USD MILLION) 98
TABLE 32 NORTH AMERICA: PHOSPHOLIPIDS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 98
TABLE 33 EUROPE: PHOSPHOLIPIDS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 98
TABLE 34 ASIA PACIFIC: PHOSPHOLIPIDS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 99
TABLE 35 LATIN AMERICA: PHOSPHOLIPIDS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 99
TABLE 36 MIDDLE EAST: PHOSPHOLIPIDS MARKET, BY REGION, 2022–2029 (USD MILLION) 99
TABLE 37 KITS & REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION) 100
TABLE 38 OTHER FORMULATION MATERIALS MARKET, BY REGION,
2022–2029 (USD MILLION) 101
TABLE 39 LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION) 103
TABLE 40 SOLID LIPID NANOPARTICLES MARKET, BY REGION, 2022–2029 (USD MILLION) 104
TABLE 41 NORTH AMERICA: SOLID LIPID NANOPARTICLES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 42 EUROPE: SOLID LIPID NANOPARTICLES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 43 ASIA PACIFIC: SOLID LIPID NANOPARTICLES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 44 LATIN AMERICA: SOLID LIPID NANOPARTICLES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 45 MIDDLE EAST: SOLID LIPID NANOPARTICLES MARKET,
BY REGION, 2022–2029 (USD MILLION) 105
TABLE 46 NANOSTRUCTURED LIPID CARRIERS MARKET,
BY REGION, 2022–2029 (USD MILLION) 106
TABLE 47 NORTH AMERICA: NANOSTRUCTURED LIPID CARRIERS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 48 EUROPE: NANOSTRUCTURED LIPID CARRIERS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 49 ASIA PACIFIC: NANOSTRUCTURED LIPID CARRIERS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 50 LATIN AMERICA: NANOSTRUCTURED LIPID CARRIERS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 51 MIDDLE EAST: NANOSTRUCTURED LIPID CARRIERS MARKET,
BY REGION, 2022–2029 (USD MILLION) 108
TABLE 52 OTHER LNP TYPES MARKET, BY REGION, 2022–2029 (USD MILLION) 109
TABLE 53 NORTH AMERICA: OTHER LNP TYPES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 109
TABLE 54 EUROPE: OTHER LNP TYPES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 109
TABLE 55 ASIA PACIFIC: OTHER LNP TYPES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 56 LATIN AMERICA: OTHER LNP TYPES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 57 MIDDLE EAST: OTHER LNP TYPES MARKET,
BY REGION, 2022–2029 (USD MILLION) 110
TABLE 58 LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION) 112
TABLE 59 LNP RAW MATERIALS MARKET FOR SIRNA, BY REGION,
2022–2029 (USD MILLION) 113
TABLE 60 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR SIRNA,
BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 61 EUROPE: LNP RAW MATERIALS MARKET FOR SIRNA,
BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 62 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR SIRNA,
BY COUNTRY, 2022–2029 (USD MILLION) 114
TABLE 63 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR SIRNA,
BY COUNTRY, 2022–2029 (USD MILLION) 114
TABLE 64 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR SIRNA,
BY REGION, 2022–2029 (USD MILLION) 114
TABLE 65 LNP RAW MATERIALS MARKET FOR MRNA, BY REGION,
2022–2029 (USD MILLION) 115
TABLE 66 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR MRNA,
BY COUNTRY, 2022–2029 (USD MILLION) 115
TABLE 67 EUROPE: LNP RAW MATERIALS MARKET FOR MRNA,
BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 68 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR MRNA,
BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 69 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR MRNA,
BY COUNTRY, 2022–2029 (USD MILLION) 117
TABLE 70 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR MRNA,
BY REGION, 2022–2029 (USD MILLION) 117
TABLE 71 LNP RAW MATERIALS MARKET FOR OTHER MOLECULES,
BY REGION, 2022–2029 (USD MILLION) 118
TABLE 72 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES,
BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 73 EUROPE: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES,
BY COUNTRY, 2022–2029 (USD MILLION) 119
TABLE 74 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES,
BY COUNTRY, 2022–2029 (USD MILLION) 119
TABLE 75 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES,
BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 76 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES,
BY REGION, 2022–2029 (USD MILLION) 120
TABLE 77 LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 122
TABLE 78 LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 122
TABLE 79 LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,
BY REGION, 2022–2029 (USD MILLION) 123
TABLE 80 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 81 EUROPE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 82 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 124
TABLE 83 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 124
TABLE 84 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 124
TABLE 85 LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY REGION,
2022–2029 (USD MILLION) 125
TABLE 86 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY,
BY COUNTRY, 2022–2029 (USD MILLION) 125
TABLE 87 EUROPE: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY,
BY COUNTRY, 2022–2029 (USD MILLION) 126
TABLE 88 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY,
BY COUNTRY, 2022–2029 (USD MILLION) 126
TABLE 89 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY,
BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 90 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY,
BY REGION, 2022–2029 (USD MILLION) 127
TABLE 91 LNP RAW MATERIALS MARKET FOR COVID-19 (COMMERCIAL APPLICATIONS),
BY REGION, 2022–2029 (USD MILLION) 128
TABLE 92 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COVID-19 (COMMERCIAL APPLICATIONS), BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 93 EUROPE: LNP RAW MATERIALS MARKET FOR COVID-19 (COMMERCIAL APPLICATIONS), BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 94 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COVID-19 (COMMERCIAL APPLICATIONS), BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 95 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COVID-19 (COMMERCIAL APPLICATIONS), BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 96 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COVID-19 (COMMERCIAL APPLICATIONS), BY REGION, 2022–2029 (USD MILLION) 129
TABLE 97 LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 130
TABLE 98 LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY REGION, 2022–2029 (USD MILLION) 130
TABLE 99 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 100 EUROPE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 101 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 102 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 103 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY REGION, 2022–2029 (USD MILLION) 132
TABLE 104 LNP RAW MATERIALS MARKET FOR COVID-19 (CLINICAL APPLICATIONS),
BY REGION, 2022–2029 (USD MILLION) 133
TABLE 105 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COVID-19 (CLINICAL APPLICATIONS), BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 106 EUROPE: LNP RAW MATERIALS MARKET FOR COVID-19 (CLINICAL APPLICATIONS), BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 107 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COVID-19 (CLINICAL APPLICATIONS), BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 108 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COVID-19 (CLINICAL APPLICATIONS), BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 109 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COVID-19 (CLINICAL APPLICATIONS), BY REGION, 2022–2029 (USD MILLION) 134
TABLE 110 LNP RAW MATERIALS MARKET FOR CANCER, BY REGION,
2022–2029 (USD MILLION) 135
TABLE 111 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CANCER,
BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 112 EUROPE: LNP RAW MATERIALS MARKET FOR CANCER,
BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 113 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CANCER,
BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 114 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CANCER,
BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 115 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CANCER,
BY REGION, 2022–2029 (USD MILLION) 137
TABLE 116 LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS,
BY REGION, 2022–2029 (USD MILLION) 138
TABLE 117 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 118 EUROPE: LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 119 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 120 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR OTHER DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 121 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR OTHER DISEASES,
BY REGION, 2022–2029 (USD MILLION) 139
TABLE 122 LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION) 141
TABLE 123 LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION) 142
TABLE 124 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 125 EUROPE: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 126 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 127 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 128 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION) 143
TABLE 129 LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY REGION, 2022–2029 (USD MILLION) 144
TABLE 130 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 131 EUROPE: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 132 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR ACADEMIC &
RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 133 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR ACADEMIC &
RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 146
TABLE 134 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR ACADEMIC &
RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION) 146
TABLE 135 LNP RAW MATERIALS MARKET FOR CDMOS, BY REGION,
2022–2029 (USD MILLION) 147
TABLE 136 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CDMOS,
BY COUNTRY, 2022–2029 (USD MILLION) 147
TABLE 137 EUROPE: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY,
2022–2029 (USD MILLION) 147
TABLE 138 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CDMOS,
BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 139 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CDMOS,
BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 140 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CDMOS,
BY REGION, 2022–2029 (USD MILLION) 148
TABLE 141 LNP SERVICES MARKET, BY SERVICE TYPE, 2022–2029 (USD MILLION) 150
TABLE 142 FORMULATION DEVELOPMENT SERVICES MARKET,
BY REGION, 2022–2029 (USD MILLION) 151
TABLE 143 MANUFACTURING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 152
TABLE 144 OTHER SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 153
TABLE 145 LNP SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION) 155
TABLE 146 LNP SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION) 156
TABLE 147 LNP SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY REGION, 2022–2029 (USD MILLION) 157
TABLE 148 LNP RAW MATERIALS MARKET, BY REGION, 2022–2029 (USD MILLION) 159
TABLE 149 LNP SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 159
TABLE 150 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 161
TABLE 151 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 161
TABLE 152 NORTH AMERICA: LNP SERVICES MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 161
TABLE 153 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY LNP TYPE,
2022–2029 (USD MILLION) 162
TABLE 154 NORTH AMERICA: LNP RAW MATERIALS MARKET,
BY MOLECULE TYPE, 2022–2029 (USD MILLION) 162
TABLE 155 NORTH AMERICA: LNP RAW MATERIALS MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 162
TABLE 156 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 163
TABLE 157 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 163
TABLE 158 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY END USER,
2022–2029 (USD MILLION) 163
TABLE 159 NORTH AMERICA: LNP SERVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 164
TABLE 160 US: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 165
TABLE 161 US: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION) 166
TABLE 162 US: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2022–2029 (USD MILLION) 166
TABLE 163 US: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 166
TABLE 164 US: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 167
TABLE 165 US: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 167
TABLE 166 US: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION) 167
TABLE 167 CANADA: LNP RAW MATERIALS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 168
TABLE 168 CANADA: LNP RAW MATERIALS MARKET, BY LNP TYPE,
2022–2029 (USD MILLION) 169
TABLE 169 CANADA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2022–2029 (USD MILLION) 169
TABLE 170 CANADA: LNP RAW MATERIALS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 169
TABLE 171 CANADA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 170
TABLE 172 CANADA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 170
TABLE 173 CANADA: LNP RAW MATERIALS MARKET, BY END USER,
2022–2029 (USD MILLION) 170
TABLE 174 EUROPE: LNP RAW MATERIALS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 171
TABLE 175 EUROPE: LNP RAW MATERIALS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 171
TABLE 176 EUROPE: LNP SERVICES MARKET, BY SERVICE TYPE, 2022–2029 (USD MILLION) 172
TABLE 177 EUROPE: LNP RAW MATERIALS MARKET, BY LNP TYPE,
2022–2029 (USD MILLION) 172
TABLE 178 EUROPE: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2022–2029 (USD MILLION) 172
TABLE 179 EUROPE: LNP RAW MATERIALS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 173
TABLE 180 EUROPE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 173
TABLE 181 EUROPE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 173
TABLE 182 EUROPE: LNP RAW MATERIALS MARKET, BY END USER,
2022–2029 (USD MILLION) 174
TABLE 183 EUROPE: LNP SERVICES MARKET BY END USER, 2022–2029 (USD MILLION) 174
TABLE 184 GERMANY: LNP RAW MATERIALS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 175
TABLE 185 GERMANY: LNP RAW MATERIALS MARKET, BY LNP TYPE,
2022–2029 (USD MILLION) 175
TABLE 186 GERMANY: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2022–2029 (USD MILLION) 176
TABLE 187 GERMANY: LNP RAW MATERIALS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 176
TABLE 188 GERMANY: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 176
TABLE 189 GERMANY: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 177
TABLE 190 GERMANY: LNP RAW MATERIALS MARKET, BY END USER,
2022–2029 (USD MILLION) 177
TABLE 191 UK: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 178
TABLE 192 UK: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION) 178
TABLE 193 UK: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2022–2029 (USD MILLION) 178
TABLE 194 UK: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 179
TABLE 195 UK: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 179
TABLE 196 UK: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 179
TABLE 197 UK: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION) 180
TABLE 198 FRANCE: LNP RAW MATERIALS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 180
TABLE 199 FRANCE: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION) 181
TABLE 200 FRANCE: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2022–2029 (USD MILLION) 181
TABLE 201 FRANCE: LNP RAW MATERIALS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 181
TABLE 202 FRANCE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 182
TABLE 203 FRANCE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 182
TABLE 204 FRANCE: LNP RAW MATERIALS MARKET, BY END USER,
2022–2029 (USD MILLION) 182
TABLE 205 ITALY: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 183
TABLE 206 ITALY: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION) 183
TABLE 207 ITALY: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2022–2029 (USD MILLION) 184
TABLE 208 ITALY: LNP RAW MATERIALS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 184
TABLE 209 ITALY: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 184
TABLE 210 ITALY: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 185
TABLE 211 ITALY: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION) 185
TABLE 212 SPAIN: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 186
TABLE 213 SPAIN: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION) 186
TABLE 214 SPAIN: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2022–2029 (USD MILLION) 186
TABLE 215 SPAIN: LNP RAW MATERIALS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 187
TABLE 216 SPAIN: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 217 SPAIN: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 218 SPAIN: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION) 188
TABLE 219 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 188
TABLE 220 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY LNP TYPE,
2022–2029 (USD MILLION) 189
TABLE 221 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2022–2029 (USD MILLION) 189
TABLE 222 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 189
TABLE 223 REST OF EUROPE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 190
TABLE 224 REST OF EUROPE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 190
TABLE 225 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY END USER,
2022–2029 (USD MILLION) 190
TABLE 226 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 192
TABLE 227 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 192
TABLE 228 ASIA PACIFIC: LNP SERVICES MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 192
TABLE 229 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY LNP TYPE,
2022–2029 (USD MILLION) 193
TABLE 230 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2022–2029 (USD MILLION) 193
TABLE 231 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 193
TABLE 232 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 194
TABLE 233 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 194
TABLE 234 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY END USER,
2022–2029 (USD MILLION) 194
TABLE 235 ASIA PACIFIC: LNP SERVICES MARKET BY END USER, 2022–2029 (USD MILLION) 195
TABLE 236 CHINA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 196
TABLE 237 CHINA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION) 197
TABLE 238 CHINA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2022–2029 (USD MILLION) 197
TABLE 239 CHINA: LNP RAW MATERIALS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 197
TABLE 240 CHINA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 198
TABLE 241 CHINA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 198
TABLE 242 CHINA: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION) 198
TABLE 243 JAPAN: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 199
TABLE 244 JAPAN: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION) 199
TABLE 245 JAPAN: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2022–2029 (USD MILLION) 200
TABLE 246 JAPAN: LNP RAW MATERIALS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 200
TABLE 247 JAPAN: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 200
TABLE 248 JAPAN: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 201
TABLE 249 JAPAN: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION) 201
TABLE 250 INDIA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 202
TABLE 251 INDIA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION) 202
TABLE 252 INDIA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2022–2029 (USD MILLION) 202
TABLE 253 INDIA: LNP RAW MATERIALS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 203
TABLE 254 INDIA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 203
TABLE 255 INDIA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 203
TABLE 256 INDIA: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION) 204
TABLE 257 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 205
TABLE 258 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY LNP TYPE,
2022–2029 (USD MILLION) 205
TABLE 259 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2022–2029 (USD MILLION) 205
TABLE 260 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 206
TABLE 261 SOUTH KOREA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 206
TABLE 262 SOUTH KOREA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 206
TABLE 263 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY END USER,
2022–2029 (USD MILLION) 207
TABLE 264 AUSTRALIA: LNP RAW MATERIALS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 207
TABLE 265 AUSTRALIA: LNP RAW MATERIALS MARKET, BY LNP TYPE,
2022–2029 (USD MILLION) 208
TABLE 266 AUSTRALIA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2022–2029 (USD MILLION) 208
TABLE 267 AUSTRALIA: LNP RAW MATERIALS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 208
TABLE 268 AUSTRALIA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,
BY TYPE,2022–2029 (USD MILLION) 209
TABLE 269 AUSTRALIA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 209
TABLE 270 AUSTRALIA: LNP RAW MATERIALS MARKET, BY END USER,
2022–2029 (USD MILLION) 209
TABLE 271 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET,
BY PRODUCT, 2022–2029 (USD MILLION) 210
TABLE 272 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET,
BY LNP TYPE, 2022–2029 (USD MILLION) 210
TABLE 273 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET,
BY MOLECULE TYPE, 2022–2029 (USD MILLION) 211
TABLE 274 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 211
TABLE 275 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 211
TABLE 276 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 212
TABLE 277 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET,
BY END USER, 2022–2029 (USD MILLION) 212
TABLE 278 LATIN AMERICA: LNP RAW MATERIALS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 213
TABLE 279 LATIN AMERICA: LNP RAW MATERIALS MARKET,
BY PRODUCT, 2022–2029 (USD MILLION) 213
TABLE 280 LATIN AMERICA: LNP SERVICES MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 213
TABLE 281 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY LNP TYPE,
2022–2029 (USD MILLION) 214
TABLE 282 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2022–2029 (USD MILLION) 214
TABLE 283 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 214
TABLE 284 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 215
TABLE 285 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 215
TABLE 286 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY END USER,
2022–2029 (USD MILLION) 215
TABLE 287 LATIN AMERICA: LNP SERVICES MARKET BY END USER,
2022–2029 (USD MILLION) 216
TABLE 288 BRAZIL: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 217
TABLE 289 BRAZIL: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION) 217
TABLE 290 BRAZIL: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2022–2029 (USD MILLION) 217
TABLE 291 BRAZIL: LNP RAW MATERIALS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 218
TABLE 292 BRAZIL: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 218
TABLE 293 BRAZIL: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 218
TABLE 294 BRAZIL: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION) 219
TABLE 295 MEXICO: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 219
TABLE 296 MEXICO: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION) 220
TABLE 297 MEXICO: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2022–2029 (USD MILLION) 220
TABLE 298 MEXICO: LNP RAW MATERIALS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 220
TABLE 299 MEXICO: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 221
TABLE 300 MEXICO: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 221
TABLE 301 MEXICO: LNP RAW MATERIALS MARKET, BY END USER,
2022–2029 (USD MILLION) 221
TABLE 302 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET,
BY PRODUCT, 2022–2029 (USD MILLION) 222
TABLE 303 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET,
BY LNP TYPE, 2022–2029 (USD MILLION) 222
TABLE 304 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET,
BY MOLECULE TYPE, 2022–2029 (USD MILLION) 223
TABLE 305 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 223
TABLE 306 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET
FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 223
TABLE 307 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET
FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 224
TABLE 308 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET,
BY END USER, 2022–2029 (USD MILLION) 224
TABLE 309 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY REGION,
2022–2029 (USD MILLION) 225
TABLE 310 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 225
TABLE 311 MIDDLE EAST: LNP SERVICES MARKET, BY SERVICE TYPE,
2022–2029 (USD MILLION) 225
TABLE 312 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY LNP TYPE,
2022–2029 (USD MILLION) 226
TABLE 313 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2022–2029 (USD MILLION) 226
TABLE 314 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 226
TABLE 315 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 227
TABLE 316 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 227
TABLE 317 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY END USER,
2022–2029 (USD MILLION) 227
TABLE 318 MIDDLE EAST: LNP SERVICES MARKET BY END USER, 2022–2029 (USD MILLION) 228
TABLE 319 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 229
TABLE 320 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY LNP TYPE,
2022–2029 (USD MILLION) 229
TABLE 321 GCC COUNTRIES: LNP RAW MATERIALS MARKET,
BY MOLECULE TYPE, 2022–2029 (USD MILLION) 229
TABLE 322 GCC COUNTRIES: LNP RAW MATERIALS MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 230
TABLE 323 GCC COUNTRIES: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE,2022–2029 (USD MILLION) 230
TABLE 324 GCC COUNTRIES: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 230
TABLE 325 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY END USER,
2022–2029 (USD MILLION) 231
TABLE 326 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET,
BY PRODUCT, 2022–2029 (USD MILLION) 231
TABLE 327 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET,
BY LNP TYPE, 2022–2029 (USD MILLION) 232
TABLE 328 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET,
BY MOLECULE TYPE, 2022–2029 (USD MILLION) 232
TABLE 329 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 232
TABLE 330 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET FOR
COMMERCIAL APPLICATIONS, BY TYPE,2022–2029 (USD MILLION) 233
TABLE 331 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET FOR
CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 233
TABLE 332 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET,
BY END USER, 2022–2029 (USD MILLION) 233
TABLE 333 AFRICA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 234
TABLE 334 AFRICA: LNP SERVICES MARKET, BY SERVICE TYPE, 2022–2029 (USD MILLION) 234
TABLE 335 AFRICA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION) 235
TABLE 336 AFRICA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2022–2029 (USD MILLION) 235
TABLE 337 AFRICA: LNP RAW MATERIALS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 235
TABLE 338 AFRICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 236
TABLE 339 AFRICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2022–2029 (USD MILLION) 236
TABLE 340 AFRICA: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION) 236
TABLE 341 AFRICA: LNP SERVICES MARKET BY END USER, 2022–2029 (USD MILLION) 237
TABLE 342 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES 238
TABLE 343 LNP RAW MATERIALS MARKET: DEGREE OF COMPETITION 241
TABLE 344 LNP SERVICES MARKET: TOP SERVICE PROVIDERS (2023) 243
TABLE 345 LNP RAW MATERIALS & SERVICES MARKET: PRODUCT FOOTPRINT 247
TABLE 346 LNP RAW MATERIALS & SERVICES MARKET: APPLICATION FOOTPRINT 248
TABLE 347 LNP RAW MATERIALS & SERVICES MARKET: SERVICE TYPE FOOTPRINT 249
TABLE 348 LNP RAW MATERIALS & SERVICES MARKET: REGION FOOTPRINT 250
TABLE 349 LNP RAW MATERIALS & SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 253
TABLE 350 LNP RAW MATERIALS & SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 254
TABLE 351 LNP RAW MATERIALS & SERVICES MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−JUNE 2024 257
TABLE 352 LNP RAW MATERIALS & SERVICES MARKET: DEALS, JANUARY 2021−JUNE 2024 258
TABLE 353 LNP RAW MATERIALS & SERVICES MARKET: EXPANSIONS,
JANUARY 2021−JUNE 2024 260
TABLE 354 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): COMPANY OVERVIEW 261
TABLE 355 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): PRODUCTS/SERVICES OFFERED 263
TABLE 356 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): DEALS,
JANUARY 2021–JUNE 2024 264
TABLE 357 MERCK KGAA: COMPANY OVERVIEW 265
TABLE 358 MERCK KGAA: PRODUCTS/SERVICES OFFERED 267
TABLE 359 MERCK KGAA: DEALS, JANUARY 2021–JUNE 2024 268
TABLE 360 MERCK KGAA: EXPANSIONS, JANUARY 2021–JUNE 2024 268
TABLE 361 EVONIK INDUSTRIES AG: COMPANY OVERVIEW 270
TABLE 362 EVONIK INDUSTRIES AG: PRODUCTS/SERVICES OFFERED 271
TABLE 363 EVONIK INDUSTRIES AG: DEALS, JANUARY 2021–JUNE 2024 272
TABLE 364 NIPPON FINE CHEMICAL CO., LTD.: COMPANY OVERVIEW 273
TABLE 365 NIPPON FINE CHEMICAL CO., LTD.: PRODUCTS/SERVICES OFFERED 274
TABLE 366 NOF CORPORATION: COMPANY OVERVIEW 276
TABLE 367 NOF CORPORATION: PRODUCTS/SERVICES OFFERED 278
TABLE 368 NOF CORPORATION: DEALS, JANUARY 2021–JUNE 2024 279
TABLE 369 FUJIFILM PHARMACEUTICALS U.S.A., INC.: COMPANY OVERVIEW 280
TABLE 370 FUJIFILM PHARMACEUTICALS U.S.A., INC.: PRODUCTS/SERVICES OFFERED 281
TABLE 371 FUJIFILM PHARMACEUTICALS U.S.A., INC.: EXPANSIONS,
JANUARY 2021–JUNE 2024 282
TABLE 372 PRECISION NANOSYSTEMS: COMPANY OVERVIEW 283
TABLE 373 PRECISION NANOSYSTEMS: PRODUCTS/SERVICES OFFERED 283
TABLE 374 PRECISION NANOSYSTEMS: PRODUCT/SERVICE LAUNCHES,
JANUARY 2021–JUNE 2024 284
TABLE 375 PRECISION NANOSYSTEMS: DEALS, JANUARY 2021–JUNE 2024 285
TABLE 376 PRECISION NANOSYSTEMS: EXPANSIONS, JANUARY 2021–JUNE 2024 285
TABLE 377 RECIPHARM AB: COMPANY OVERVIEW 286
TABLE 378 RECIPHARM AB: PRODUCTS/SERVICES OFFERED 287
TABLE 379 RECIPHARM AB: DEALS, JANUARY 2021–JUNE 2024 287
TABLE 380 EMERGENT: COMPANY OVERVIEW 288
TABLE 381 EMERGENT: PRODUCTS/SERVICES OFFERED 289
TABLE 382 EMERGENT: DEALS, JANUARY 2021–JUNE 2024 290
TABLE 383 EUROAPI: COMPANY OVERVIEW 291
TABLE 384 EUROAPI: PRODUCTS/SERVICES OFFERED 292
TABLE 385 CAYMAN CHEMICAL: COMPANY OVERVIEW 293
TABLE 386 CAYMAN CHEMICAL: PRODUCTS/SERVICES OFFERED 293
TABLE 387 CORDENPHARMA: COMPANY OVERVIEW 294
TABLE 388 CORDENPHARMA: PRODUCTS/SERVICES OFFERED 294
TABLE 389 CORDENPHARMA: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–JUNE 2024 295
TABLE 390 CORDENPHARMA: DEALS, JANUARY 2021–JUNE 2024 295
TABLE 391 CORDENPHARMA: EXPANSIONS, JANUARY 2021–JUNE 2024 295
TABLE 392 GATTEFOSSÉ: COMPANY OVERVIEW 296
TABLE 393 GATTEFOSSÉ: PRODUCTS/SERVICES OFFERED 296
TABLE 394 ACUITAS THERAPEUTICS: COMPANY OVERVIEW 297
TABLE 395 ACUITAS THERAPEUTICS: PRODUCTS/SERVICES OFFERED 297
TABLE 396 ACUITAS THERAPEUTICS: DEALS, JANUARY 2021–JUNE 2024 298
TABLE 397 IOI OLEO GMBH: COMPANY OVERVIEW 299
TABLE 398 IOI OLEO GMBH: PRODUCTS/SERVICES OFFERED 300
LIST OF FIGURES
FIGURE 1 RESEARCH DESIGN 34
FIGURE 2 LNP RAW MATERIALS & SERVICES MARKET: BREAKDOWN OF PRIMARIES 36
FIGURE 3 LNP RAW MATERIALS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023 37
FIGURE 4 LNP SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023 37
FIGURE 5 MARKET SIZE ESTIMATION (RAW MATERIALS): APPROACH 1
(COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023 38
FIGURE 6 MARKET SIZE ESTIMATION (SERVICES): APPROACH 1
(COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023 39
FIGURE 7 ILLUSTRATIVE EXAMPLE OF NOF CORPORATION: REVENUE SHARE
ANALYSIS (2023) 39
FIGURE 8 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 40
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 41
FIGURE 10 LNP RAW MATERIALS MARKET (SUPPLY SIDE): CAGR PROJECTIONS 42
FIGURE 11 LNP SERVICES MARKET (SUPPLY SIDE): CAGR PROJECTIONS 43
FIGURE 12 DATA TRIANGULATION METHODOLOGY 44
FIGURE 13 LNP RAW MATERIALS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION) 46
FIGURE 14 LNP RAW MATERIALS MARKET, BY LNP TYPE, 2024 VS. 2029 (USD MILLION) 47
FIGURE 15 LNP RAW MATERIALS MARKET, BY MOLECULE TYPE,
2024 VS. 2029 (USD MILLION) 47
FIGURE 16 LNP RAW MATERIALS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 48
FIGURE 17 LNP RAW MATERIALS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 48
FIGURE 18 LNP SERVICES MARKET, BY SERVICE TYPE, 2024 VS. 2029 (USD MILLION) 49
FIGURE 19 LNP SERVICES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 49
FIGURE 20 LNP RAW MATERIALS & SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 50
FIGURE 21 INCREASING USE OF LIPID NANOPARTICLES IN RNA-BASED THERAPIES
TO PROPEL LNP RAW MATERIALS MARKET 51
FIGURE 22 IONIZABLE LIPIDS ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 52
FIGURE 23 JAPAN IS EXPECTED TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 53
FIGURE 24 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD 54
FIGURE 25 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD 54
FIGURE 26 LNP RAW MATERIALS & SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55
FIGURE 27 REVENUE SHIFT AND NEW REVENUE POCKETS FOR LNP RAW MATERIAL MANUFACTURERS 61
FIGURE 28 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION STRATEGY PREFERRED
BY PROMINENT COMPANIES 64
FIGURE 29 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING
MANUFACTURING PHASE 65
FIGURE 30 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING FORMULATION DEVELOPMENT & MANUFACTURING PHASE 67
FIGURE 31 LNP RAW MATERIALS & SERVICES MARKET: ECOSYSTEM ANALYSIS 68
FIGURE 32 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR LIPID NANOPARTICLE PATENTS (JANUARY 2014–DECEMBER 2023) 73
FIGURE 33 LNP RAW MATERIALS & SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 82
FIGURE 34 NORTH AMERICA: LNP RAW MATERIALS MARKET SNAPSHOT 160
FIGURE 35 ASIA PACIFIC: LNP RAW MATERIALS MARKET SNAPSHOT 191
FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN LNP RAW MATERIALS MARKET,
2019–2023 (USD MILLION) 240
FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN LNP RAW MATERIALS
MARKET (2023) 241
FIGURE 38 LNP RAW MATERIALS & SERVICES MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 245
FIGURE 39 LNP RAW MATERIALS & SERVICES MARKET: COMPANY FOOTPRINT 246
FIGURE 40 LNP RAW MATERIALS & SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 252
FIGURE 41 EV/EBITDA OF KEY VENDORS 254
FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 255
FIGURE 43 LNP RAW MATERIALS & SERVICES MARKET: BRAND/PRODUCT
COMPARATIVE ANALYSIS 256
FIGURE 44 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): COMPANY SNAPSHOT (2023) 262
FIGURE 45 MERCK KGAA: COMPANY SNAPSHOT (2023) 266
FIGURE 46 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2023) 271
FIGURE 47 NIPPON FINE CHEMICAL CO., LTD.: COMPANY SNAPSHOT (2023) 273
FIGURE 48 NOF CORPORATION: COMPANY SNAPSHOT (2023) 277
FIGURE 49 FUJIFILM PHARMACEUTICALS U.S.A., INC.: COMPANY SNAPSHOT (2023) 281
FIGURE 50 RECIPHARM AB: COMPANY SNAPSHOT (2023) 286
FIGURE 51 EMERGENT: COMPANY SNAPSHOT (2023) 289
FIGURE 52 EUROAPI: COMPANY SNAPSHOT (2023) 292
FIGURE 53 IOI OLEO GMBH: COMPANY SNAPSHOT (2023) 300
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11